Skip to main content
OpenTrials
Completed

NCT Number: NCT01999400

Correlation of Mesalamine Pharmacokinetics With Local Availability

This study is designed to provide data to the FDA correlating pharmacokinetics with local availability of medications within the gastrointestinal tract. This study will support the establishment of scientifically based standards for evaluating drugs which act locally within the gastrointestinal tract. Specific objectives of this study are to: (1) quantify how the plasma concentrations of mesalamine, an agent used to treat inflammatory bowel disease, are correlated with the concentrations in gastrointestinal fluids; and (2) improve the physiologically based models for drug absorption from the intestine. Information from this study in concert with in vitro dissolution data will be used to evaluate in vivo-in vitro correlation (IVIVC) for concentrations in plasma and intestinal lumen and dissolution of mesalamine products.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Local Drug Concentration in Gastrointestinal Tract

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Michigan

Ann Arbor, Michigan, 48109, United States

About this study

This study evaluated the pharmacokinetics of mesalamine and its major metabolite of mesalamine known as N-acetyl-mesalamine in plasma. Mesalamine is available in different formulations that control the rate at which they are released in the gastrointestinal tract. Three formulations of mesalamine, Pentasa, Apriso, and Lialda, were studied in the crossover phase, while an oral solution formulation of mesalamine was studied in the single-arm phase. Each subject participated in a crossover phase study with one of the three formulations assigned at random using block randomization. Then the subject entered the single-arm phase study. After participation in one crossover phase study and one single-arm phase study, the subject could opt to participate in crossover phase studies using the other formulations also chosen at random until all three formulations were studied. The single-arm phase study was not repeated on returning subjects who participated in more than one crossover phase study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults age 18 to 55.
  • Male or female voluntarily able to give informed consent.
  • Body mass index (BMI) 18.5 to 35.

Exclusion criteria

  • Adults unable to consent for themselves or mentally incapacitated.
  • Prisoners.
  • Significant clinical illness within 3 weeks prior to Screening.
  • Use of concomitant medications within 2 weeks prior to receiving study drug, including but not limited to prescription drugs, herbal and dietary supplements, over the counter medications, and vitamins. Oral contraception is permitted.
  • History of gastrointestinal surgery.
  • History of allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the ingredients of Asacol, Pentasa, Apriso, or Lialda.
  • History of severe allergic diseases including drug allergies, with the exception of seasonal allergies.
  • Any other factor, condition, or disease, including, but not limited to, cardiovascular, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient or impact the validity of the study results.
  • History of drug addiction or alcohol abuse within the past 12 months.
  • Pregnant or lactating females.
  • Surgery within the past 3 months.
  • Received an investigational drug within 60 days prior to receiving the study drug.
  • Any clinically significant abnormal lab values during Screening.

Treatment and study plan

Pentasa 500 mg capsule x 2 with 240 mL water; single dose

Drug

Apriso 375 mg capsule x 3 with 240 mL water; single dose

Drug

Lialda 1200 mg tablet x 1 with 240 mL water; single dose

Drug

Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose

Drug

Primary outcomes

  1. The AUC of Mesalamine in Plasma

    Time frame: 0 hours pre-dose and up to 96 hours post-dose

    The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.

  2. The AUC of Metabolite (N-acetyl-mesalamine) in Plasma

    Time frame: 0 hours pre-dose and up to 96 hours post-dose

    The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of N-acetyl-mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.

Secondary outcomes

  1. The AUC of Mesalamine in Distal Jejunum

    Time frame: 0 hours pre-dose and up to 7 hours post-dose

    The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.

  2. The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum

    Time frame: 0 hours pre-dose and up to 7 hours post-dose

    The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • Food and Drug Administration (FDA)

Registry information

Important dates

Study start
2012
Primary completion
2015
Study completion
2017
First posted
Dec 3, 2013
Registry last updated
May 15, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.